Holen Sie sich die Stockscreener-App
1.09
3.81%
0.04
Vorhandelsmarkt:
1.08
-0.01
-0.92%
Schlusskurs vom Vortag:
$1.05
Offen:
$1.06
24-Stunden-Volumen:
1.44M
Relative Volume:
0.69
Marktkapitalisierung:
$125.73M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.6606
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+0.93%
1M Leistung:
+0.00%
6M Leistung:
-34.73%
1J Leistung:
-52.19%
1-Tages-Spanne:
$1.04
$1.10
1-Wochen-Bereich:
$1.03
$1.12
52-Wochen-Spanne:
$0.6611
$2.31
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.09 | 121.12M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Healthy Upside Potential: Fate Therapeutics Inc (FATE) - Setenews
Fate Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Fast Profit Portfolio Plans - earlytimes.in
Fate Therapeutics reports positive lupus treatment data at ASH meeting - Investing.com
Fate Therapeutics reports positive lupus treatment data at ASH meeting By Investing.com - Investing.com Canada
Fate Therapeutics, Inc. Presents Updated Phase 1 Clinical Data of FT819 Off-The-Shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-The-Shelf Car T-Shelf CAR T-Cell Programs - marketscreener.com
Fate Therapeutics (NASDAQ:FATE) Stock Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
How Fate Therapeutics Inc. stock valuations compare to rivalsWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Why Fate Therapeutics Inc. stock remains on buy listsWatch List & Safe Entry Point Identification - Newser
Will Fate Therapeutics Inc. stock benefit from sector rotationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Published on: 2025-12-02 03:44:47 - Newser
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Check Out Fate Therapeutics Inc (FATE)’s Trade Data Rather Than the Analysts’ Views - Setenews
Fate Therapeutics (NASDAQ:FATE) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 - Quiver Quantitative
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation - simplywall.st
Cantor Fitzgerald Issues Positive Outlook for FATE Earnings - MarketBeat
Multi factor analysis applied to Fate Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Tools to monitor Fate Therapeutics Inc. recovery probabilityBuy Signal & Growth Oriented Trade Recommendations - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
Will Fate Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Is Fate Therapeutics Inc. stock undervalued vs historical averagesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Fate Therapeutics Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Will Fate Therapeutics Inc. see short term momentumEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts - TipRanks
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-16 18:05:52 - newser.com
Will Fate Therapeutics Inc. stock recover faster than market2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities - The Globe and Mail
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks - MSN
Why Fate Therapeutics Inc. stock remains a top recommendationPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturns2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - MSN
Fate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results - MarketBeat
Fate Therapeutics: Q3 Earnings Snapshot - Connecticut Post
Analyzing drawdowns of Fate Therapeutics Inc. with statistical tools2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating - 富途牛牛
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):